5 Chronic Lymphocytic Leukemia Clinical Trials in Denver, CO (2026)

Q: How do I join a clinical trial in Denver?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Denver research site will contact you.

Recruiting Chronic Lymphocytic Leukemia Studies in Denver

NCT06136559Recruiting

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma...

Denver, COPHASE31,200 participantsMerck Sharp & Dohme LLC

View Study Details

NCT05131022Recruiting

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies....

Denver, COPHASE1572 participantsNurix Therapeutics, Inc.

View Study Details

NCT07509151Recruiting

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

The purpose of this study is to evaluate the therapeutic benefit and safety of subcutaneous (SC) Surovatamig monotherapy as consolidation therapy in patients with Chronic Lymphocytic Leukaemia (CLL)/ ...

Denver, COPHASE3420 participantsAstraZeneca

View Study Details

NCT04830137Recruiting

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies....

Denver, COPHASE1248 participantsNurix Therapeutics, Inc.

View Study Details

NCT07221500Recruiting

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent...

Denver, COPHASE2100 participantsNurix Therapeutics, Inc.

View Study Details

About Chronic Lymphocytic Leukemia Clinical Trials in Denver

Chronic lymphocytic leukemia (CLL) is a slow-growing cancer of the blood and bone marrow that affects B lymphocytes. It is the most common type of adult leukemia. Treatment options include targeted therapies, chemotherapy, and immunotherapy.

There are currently 5 chronic lymphocytic leukemia clinical trials recruiting participants in Denver, CO. These studies are seeking a combined 2,540 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Nurix Therapeutics, Inc., AstraZeneca. Clinical trial participation is free and participants receive study-related medical care at no cost.

Chronic Lymphocytic Leukemia Clinical Trials in Denver — FAQ

Are there chronic lymphocytic leukemia clinical trials in Denver?

Yes, there are 5 chronic lymphocytic leukemia clinical trials currently recruiting in Denver, CO. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Denver?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Denver research site will contact you about next steps.

Are clinical trials in Denver free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Denver studies also compensate for your time and travel.

What chronic lymphocytic leukemia treatments are being tested?

The 5 active trials in Denver are testing new therapies including novel drugs, biologics, and treatment approaches for chronic lymphocytic leukemia.

Data updated October 18, 2026 from ClinicalTrials.gov